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Departments of Pharmacognosy, 2Pharmacology, and 3Medicinal Chemistry, and Research Institute of
Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
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Abstract
Microbial transformation of natural products is a well established model for mammalian metabolism.
Salvinorin A, a diterpenoid isolated from the hallucinogenic mint Salvia divinorum Epling & Játiva-M
(Lamiaceae), is a potent non-nitrogenous κ-opioid receptor agonist. The metabolism of salvinorin A has still
not yet been well established. Thirty fungal species were screened for the ability to metabolize salvinorin A.
We observed that salvinorin A undergoes fast hydrolysis of the acetate group at carbon atom C2, resulting
in formation of the pharmacologically inactive product, salvinorin B. Ex vivo experiments were also performed using organelle fractions isolated from rat liver and brain. Crude tissue homogenate and individual
organelles show that the primary route of salvinorin A metabolism is hydrolysis to salvinorin B. No metabolic transformation of salvinorin B was observed in these studies.
Keywords: In vitro metabolism; microbial transformation; Salvia divinorum; salvinorin A

Introduction
The diterpenoid salvinorin A is a natural product with
hallucinogenic properties (Valdes et al., 1983). It has
been isolated from Mexican sage Salvia divinorum
Epling & Játiva-M (Labiatae), the only known hallucinogenic species of the Salvia genus. Salvinorin A attracted
interest after Roth and co-workers (2002) reported that
it is a selective and highly potent naturally occurring
-opioid receptor agonist. It has become a lead compound in searches for new drugs to combat psychiatric
disorders such as schizophrenia, or Alzheimer’s or other
dementias, in which -opioid receptors are believed to
be involved (Sheffler & Roth, 2003). In experiments with
monkeys addicted to cocaine, -opioid agonists reduce
cocaine craving (Mello & Negus, 2000). Recent results
show that salvinorin A, when given to rats along with
cocaine, attenuates cocaine-induced locomotor activity
(Chartoff et al., 2008).
The in vivo metabolism of salvinorin A is not fully
understood (Babu et al., 2008). Although studies

with isolated body fluids from primates and humans
incubated with salvinorin A revealed salvinorin B as
a metabolite (Schmidt et al., 2005b), in vivo pharmacokinetic experiments with nonhuman primates failed
to detect salvinorin B or any other metabolite in the
bloodstream (Schmidt et al., 2005a). Prompted by
these conflicting observations, we undertook studies
of the fungal transformation and ex vivo metabolism
with salvinorin A.
Smith and Rosazza were the first to propose microbes
(fungi) as a model for mammalian metabolism (Sebek,
1982). Metabolites from fermentation are similar to
those released in phase I (functionalization), or more
rarely phase II (conjugation), of xenobiotic modification by mammalian enzymes (Abourashed et al., 1999;
Hanson, 1992). Microbial transformation of organic
compounds is also a convenient method of obtaining
structurally novel leads for drug discovery. The classes
of chemicals being enzymatically modified range from
simple monoterpenoids (Miyazawa et al., 2003), sesquiterpenoids (artemisinin) (Parshikov et al., 2006), and
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aromatic compounds (Orabi et al., 1999) to structurally
more complex molecules, such as alkaloids (morphine) (Stabler et al., 2001), higher terpenoids, antibiotics, or marine natural products (e.g., sarcophine)
(El Sayed et al., 1998). ent-Kaurenes and gibbererellins
are among the most studied terpenoids utilizing microbial systems (Hanson, 1992). Xenobiotic inactivation in
mammalian systems usually occurs in the liver, where
hydroxylation, reduction, oxidation, or hydrolysis leads
to increased polarity of compounds for better water
solubility and eventual excretion (Venisetty & Ciddi,
2003). The brain is also a place of drug metabolism,
where efflux pumps effectively remove drugs from its
space. For these reasons our ex vivo studies focused on
these organs.
The goal of this study was to find the metabolites of
salvinorin A using an analytical model for mammalian
metabolism. Classical methods of searching for drug
metabolites such as tracking down the radioactive label,
or analysis of urine and other body fluids, still suffer
from several constraints. In this case, one of them is lack
of appropriately radiolabeled salvinorin A, still a challenging problem. The potency and unknown side effects
of this psychedelic agent also limit the amounts that can
be administered to animals or human volunteers, making a search for metabolites difficult. We are reporting
here microbial transformation as a potential method of
identifying salvinorin A metabolites.

Materials and methods
General experimental procedures
Mass spectra of crude extracts were generated by
liquid chromatography-mass spectrometry (LC-MS)
(Bruker Daltonik microTOF; Leipzig, Germany).
Analysis was performed using a 150 × 4. 6 mm C8 column (Phenomenex Luna; Torrance, CA) with 3 m
particle size and a linear gradient ranging from 20% of
MeCN to 100% over 20 min. The spectrometer was furnished with a photodiode array detector (Agilent 1100;
Palo Alto, CA). Positive ionization mode was used in
high-resolution electrospray ionization (HR-ESI)-MS
analysis. Nuclear magenetic resonance (NMR) spectra
were recorded on a 600 MHz Varian Innova instrument
with a 3 mm Nalorac dual broadband probe. The NMR
sample of salvinorin B was dissolved in acetonitriled3. Chemical shifts were calibrated to residual solvent
resonances. NMR resonance assignments of salvinorin
B were according to Giner et al. (2007). Thin layer chromatography (TLC) of transformation products was
performed with Merck HF254 silica gel plates, developed
using a mobile phase composed of hexanes and ethyl
acetate 1:1, v/v, and visualized by dipping in a 10%

solution of vanillin–sulfuric acid reagent (1 g of vanillin
in 40 mL of EtOH and 0.5 mL of conc. H2SO4), followed
by heating at 120°C.
Chemicals
All chemicals were purchased from Fisher Scientific
except for Difco potato dextrose broth (Becton,
Dickinson and Co., Sparks, MD). Salvia divinorum was
purchased from the Salvia divinorum Research Center,
Malibu, CA, USA, and deposited in the Department
of Pharmacognosy plant repository (voucher specimen number FH4-408-07). Crude plant extract was
obtained through exhaustive extraction of 500 g of dry
plant material with 6000 mL of acetone (3 × 2000 mL).
Solvent was removed in vacuo at 35°C and reconstituted in ethanol for subsequent crystallization. After
24 h, crystals were filtered and washed with hexane to
yield 95% pure salvinorin A. Salvinorin B was prepared
as described elsewhere (Chavkin et al., 2004). Briefly,
1 g of salvinorin A was dissolved in 500 mL of MeOH,
1 g of K2CO3 was added, and the mixture was stirred for
36 h at room temperature. The precipitate of 95% pure
salvinorin B was then filtered and dried under vacuum
for further use.
Chromatographic conditions
Residues obtained from liquid extraction of microbial cultures were dissolved in acetonitrile (MeCN)
and filtered through a 0.2 µm high-performance
liquid chromatography (HPLC) filter (Millex-GN;
Bedford, MA) prior to analysis. Analytical profiling of
extracts was performed using HPLC (Waters Alliance;
Waters Corp., Milford, MA) furnished with a Synergi
Fusion-RP C18 column (150 × 10 mm, 4 µm particle
size) (Phenomenex). The mobile phase composition
consisted of phase A – MeCN, and phase B – water. The
gradient started at 20% of phase A and increased to 80%
over 30 min, and further to 100% of MeCN in the next
10 min, followed by 10 min of wash with 100% MeCN.
Salvinorin A retention time was 20.7 min and salvinorin B
15.6 min. Isolation of metabolites was performed also
by HPLC, where the crude extract was loaded onto a
Phenomenex C8 (250 × 10 mm, 5 µm particle size) column connected to an HPLC (Delta Prep 4000; Waters
Corp.) system equipped with a dual wavelength detector (Model 2487; Waters Corp.). The mobile phase composition consisted of an MeCN:H2O (40:60) isocratic
system. Retention time for salvinorin A was 11.3 min
and salvinorin B 4.1 min. For detection, ultraviolet (UV)
radiation,  = 210 and 254 nm, was used. For analysis of extracts from ex vivo experiments, a Waters C18
XTerra column (100 × 7. 6 mm, 5 m particle size) was
used, where salvinorin A and B retention times were
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16.3 min and 12.9 min, respectively. The mobile phase
composition was the same as for the analytical method
presented above.
Microorganisms
The following fungal strains were chosen for the preliminary screening and were purchased from the American
Type Culture Collection (ATCC, Rockville, MD): Mucor
plumbeus ATCC 8773, Aspergillus niger ATCC 9142,
Aspergillus flavus ATCC 9170, Cunninghamella bainieri ATCC 9244, Cunninghamella echinulata ATCC
9245, Mucor ramannianus ATCC 9628, Saccharomyces
cerevisiae ATCC 9763, Rhizopus oryzae ATCC 11145,
Rhodococcus rhodochrous ATCC 12674, Fusarium
solani ATCC 12823, Beauveria bassiana ATCC 13144,
Mortierella zonata ATCC 13309, Curvularia lunata
ATCC 13633, Rhizopus stolonifer ATCC 14037, Aspergillus
niger ATCC 16888, Aspergillus ochraceus ATCC 18412,
Aspergillus ochraceus ATCC 18500, Mucor mucedo ATCC
20094, Rhodotorula mucilaginosa ATCC 20129, Absidia
glauca ATCC 22752, Aspergillus ochraceus ATCC 22947,
Rhizopus stolonifer ATCC 24795, Verticillium lecanii
ATCC 28300, Rhizopus oryzae ATCC 34121, Curvularia
lunata ATCC 34690, Cunninghamella echinulata ATCC
36190, Cunninghamella echinulata ATCC 10028b,
Cunninghamella echinulata ATCC 11585a, Rhizopus stolonifer ATCC 6227a, and Rhizopus stolonifer ATCC 6227b.
Microbial transformation screening and scale-up
For all stages of fermentation the same medium containing: peptone, yeast extract, potassium phosphate,
sodium chloride, and dextrose in weight ratio 1:1:1:1:4
dissolved in double deionized water was used, and the
pH was adjusted to 7.2 by the addition of 0.1 M potassium
hydroxide. Medium was autoclaved at 121°C for 15 min.
Cultures were grown according to the standard two-stage
procedure (Abourashed et al., 1999). Fermentation was
inoculated to 125 mL conical Bellco Delong steel capped
flasks containing 25 mL of broth, where the initial stage
was run for 72 h, followed by transfer to a fresh medium.
After 1 day of culture, 5 mg of salvinorin A was added, with
the final concentration 0.25 mg/mL in dimethylsulfoxide
(DMSO) (stage II). The second stage was allowed to proceed for 14 days at 28°C on a rotary shaker (C24KC refrigerated shaker; New Brunswick Scientific, Edison, NJ)
at 200 rpm. Control experiments with the same set of
microorganisms containing vehicle only were conducted
simultaneously. After 14 days of incubation the culture
broth was filtered and extracted with ethyl acetate. The
organic solvent was evaporated in vacuo at 35°C and samples were later re-dissolved in acetonitrile for analysis.
Scale-up experiments were performed under the same
experimental conditions with a 10-fold increase in broth

volume and substrate content per selected microorganism. The kinetics of salvinorin A conversion was measured by sampling 1 mL of culture broth per day, followed
by extraction with ethyl acetate. The organic extract was
subsequently injected into an analytical HPLC apparatus
and the peak area was measured with regard to standard
curves of salvinorins A and B.
Ex vivo assays
Adult Sprague-Dawley rats (Harlan, 250–300 g), maintained in a 12 h light/dark cycle and fed ad libitum,
were used for the study. The protocol for the study was
approved by the University of Mississippi Institutional
Animal Care and Use Committee (IACUC). Rat brain and
liver were excised upon decapitation. After dissection, the
tissues were weighed and immediately homogenized in
ice-cold buffer (10 mM Tris and 0.25 M sucrose, pH 7.2).
Homogenates were further fractionated by centrifugation at 1000 × g for 10 min, 10,000 × g for 20 min (Allegra
25R centrifuge; Beckmann Coulter, Fullerton, CA), and
100,000 × g for 60 min (Optima Max ultracentrifuge;
Beckmann Coulter) to obtain fractions of nuclei, mitochondria, and microsomes, respectively. Assays were
carried out with homogenates of each organ or respective
organelle fractions in 1 mL of 10 mM Tris buffer (150 mM
NaCl, pH 7.2). Treatment was done in triplicate whereas
controls were done in duplicate. Treatment samples were
incubated with 4 L (10 mmol) salvinorin A dissolved in
DMSO (50 mM stock). Two types of controls were used in
the study: the first comprised only buffer and salvinorin A
to evaluate the stability of salvinorin A in blank Tris
buffer, and the second contained the respective tissue/
organelle fraction and vehicle. The assay was carried
out for 1 h at 37°C on a rotary shaker (Thermomixer R;
Eppendorf, Westbury, NY) at 800 rpm. The reaction was
terminated by centrifugation at 4°C at 10,000 × g for 5 min.
The supernatant was then collected and stored at −20°C
for further HPLC analysis.
Salvinorin B
Salvinorin B was isolated as a white solid, HR-MS m/z
[M + H]+ 391.1518 (calcd for C21H26O7 390.1679); NMR
spectroscopic data matched those previously published
(Giner et al., 2007).

Results and discussion
Microbial transformation of salvinorin A
Microorganisms used for the experiment were previously reported capable of transforming diterpenoids in
reactions such as hydroxylation, oxidation, reduction, or
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Scheme 1. Possible routes of hydrolytic transformations of salvinorin A.

epoxidation (Hanson, 1992). A preliminary screening
of salvinorin A (5 mg) showed that most of the microorganisms transformed the substrate into salvinorin B
(Scheme 1). TLC monitoring of the transformation process revealed that some microbes were capable of transforming approximately 50% of the substrate within the
first 24 h after addition of salvinorin A into a medium
(data not shown). However, the conversion efficiency
varied between organisms, so, for example, C. lunata,
M. zonata, R. rhodochrous, M. plumbeus, A. niger,
C. bainieri, and R. stolonifer were capable of complete
hydrolysis of salvinorin A to salvinorin B within 14 days
of incubation. Approximately 70% of salvinorin A was
metabolized into salvinorin B by A. glauca, A. ochraceus, and B. bassiana. M. mucedo, M. ramannianus, and
R. oryzae hydrolyzed approximately 50% of the substrate
in this time period. By contrast, V. lecanii, C. lunata, and
C. echinulata poorly transformed salvinorin A (only
about 10–15% of conversion to salvinorin B) over 14 days
of incubation.
Scale-up experiments involved four species and
all were carried out for 14 days: C. bainieri, M. zonata,
R. stolonifer, and A. glauca, which were chosen based on
their TLC and analytical HPLC chromatographic profiles.
LC-MS analysis was performed to confirm the presence

of salvinorin B in fermentation extracts. HPLC profiles
of extracts from scale-up experiments showed the exact
rate of transformation of salvinorin A into salvinorin B.
C. bainieri converted salvinorin A to salvinorin B in 100%
yield (Figure 1), and was used later on to determine the
kinetics of the conversion. The presented data (Figure 2)
indicate that 50% of salvinorin A was hydrolyzed to
salvinorin B within 48 h, and that it was almost completely
converted 6 days after adding substrate to the culture.
M. zonata, which also gave 100% conversion of salvinorin
A to salvinorin B (~45 mg), was used to isolate and identify the metabolite. NMR spectra of the metabolite were
in full agreement with published data, and confirmed
that the obtained product was indeed salvinorin B (Giner
et al., 2007). R. stolonifer produced salvinorin B in 90%
yield, but no other products were detected, comparing with the control strains. The preparative yield of A.
glauca did not correlate with that of the screening scale,
with only 37% conversion of salvinorin A to salvinorin B.
To make sure that salvinorin B was indeed the final
product of microbial metabolism, we performed another
experiment where we incubated all 30 microorganisms that we used to biotransform salvinorin A with
pure salvinorin B. Attempts to demonstrate further
transformation of this compound were unsuccessful.
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The screening experiment revealed that none of the 30
species was able to further metabolize salvinorin B. HPLC
analysis of additional scale-up experiments involving C.
echinulata and A. glauca confirmed these results. Both
salvinorin A and salvinorin B proved to be stable in the
medium with the absence of microorganisms (substrate
control), ruling out any possibility of medium-influenced
hydrolysis or decomposition of the substrate.
There has been only one report indicating that
salvinorin A is rapidly hydrolyzed in vitro to its inactive metabolite, salvinorin B. Schmidt and co-workers
(2005a) described the formation of salvinorin B within
monkey plasma incubated with salvinorin A at 37°C. The
authors reported that within the first 15 min of incubation, approximately 20% of salvinorin A was converted

to salvinorin B, where blood esterases were mainly
responsible for that conversion. They did not observe
any other metabolites (Schmidt et al., 2005a). Such a
short presence of salvinorin A under in vitro conditions
was also confirmed by in vivo experiments conducted by
Pichini and co-workers (2005). The average recovery of
salvinorin A from saliva, 1 h post-treatment, was about
18.0 ng/mL, and about 6.7 ng/mL from urine (n = 2).
The total amount of salvinorin A extracted from urine
after that time was about 0.8% of the administered dose
(0.5 mg). Blood samples were not analyzed in that study
(Pichini et al., 2005). An in vivo experiment performed
by Schmidt et al. (2005b) also showed rapid elimination of salvinorin A in the rhesus monkey, which varied
with gender. For the male rhesus monkey, the elimination half-life was 37.9 ± 5.6 min, whereas for the female
it was much slower, 80.0 ± 13.1 min. In none of these
in vivo experiments, however, did the authors observe
the formation of salvinorin B, or any other metabolites
of salvinorin A. These should have been detectable in
the analyzed matrices (Pichini et al., 2005; Schmidt et al.,
2005b).
In our experiments we focused on the microbial model
as that which could potentially reflect a wider variety of
the phase I enzymes, resembling the situation present
in more specific organs such as the liver. Although the
use of a variety of microbial species was aimed to assess
possible diverse enzymatic catalysis of salvinorin A
into more oxidized products than salvinorin B, we were
unable to show such transformations. At this point we
conclude that rapid decay of the hallucinogenic effect
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of salvinorin A, after administration, is most probably
due to a fast and non-specific hydrolysis of the acetate
group at C-2 to form salvinorin B. Recent experiments
with 2-methoxymethyl salvinorin B, which has an ether
instead of an ester bond, shows that its metabolism is
greatly slowed by the presence of a hydrolysis-resistant
group at C-2 (Wang et al., 2008).
Ex vivo metabolism of salvinorin A
We carried out ex vivo metabolism studies using rat liver
crude homogenate. Incubation of salvinorin A with liver
crude homogenate resulted in complete hydrolysis of
substrate to salvinorin B. Further fractionation of the
homogenate to nuclei, mitochondria, and microsomes
confirmed the same reaction, with 100% conversion
in all fractions. Incubation of salvinorin A with cytosol
also gave a similar result. The ubiquity of hydrolases in
liver tissue gave the expected deacetylation product of
salvinorin A. While the liver is the primary site of drug
metabolism in many organisms, we were expecting to
observe additional routes of metabolism, such as oxidation by cytochrome P450, or conjugation with glucuronic
acid. However, none of these reactions were detected.
Brain tissue is also a place of drug metabolism, but unlike
the liver, it has a different enzyme composition. In our
experiment, enzymes from brain homogenate metabolized salvinorin A as efficiently as those from the liver.
The incubation of individual organelles with salvinorin
A resulted in full hydrolysis to salvinorin B. Incubation
with the nuclear and mitochondrial fractions as well
as with microsomes and cytosol gave the same result.
Although the cytosol is rich in phase II enzymes, we did
not observe any transformation product of salvinorin A,
characteristic of phase II metabolism.
There is no noticeable difference in metabolism of
salvinorin A between brain and liver, two functionally
distinct tissues. Although both the liver and the brain
contain enzymes of phase I of drug metabolism (cytochrome P450, epoxyhydrolases, dehydrogenases, various types of oxidases, and oxidoreductases), the brain
has an effective way of removing drugs from its space, for
example by using the P-glycoprotein efflux pump (Allt &
Lawrenson, 2000; Cordon-Cardo et al., 1989). Whether
there is any deposition of salvinorin B in vivo in any of
the analyzed tissues remains unknown.

Conclusions
In conclusion, we are reporting here that the biotransformation of salvinorin A, using two independent
models of mammalian metabolism (fungi/rat liver and
brain), yielded salvinorin B as the same metabolite.
The metabolite concentration, however, varied between

the models. While the substrate is more available to free
enzyme(s) in ex vivo experiments, fungi, on the other
hand, vary in mechanisms of substrate uptake and
enzyme composition, which may have affected the rate
of salvinorin B production. Attempts to demonstrate
metabolism of salvinorin B did not yield any further
detectable metabolites in either model. Although microbial transformation in general is a good method of derivatization of natural products, it was of limited utility in
this case. There is a need for appropriately radiolabeled
salvinorin A, which would be a highly valuable tool for
tracking metabolites in in vivo models.
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